Sustainability at Biocon

Asset-light entry into vaccines through SILS alliance BBL RIGHTS Biocon 1 SII SERUM INSTITUTE OF INDIA 1 Access to 100m doses of vaccines annually for 15 years 2 of the SILS portfolio for global markets Commercialization rights Biocon Biologics 3 BBL to have committed revenue stream and related margins from H2 FY23 Alliance to commercialize SILS COVID portfolio and other next generation vaccines Note: Transaction pending regulatory approvals 19

View entire presentation